HTG Molecular Diagnostics
HTGM
HTGM was delisted on the 14th of June, 2023.
47 hedge funds and large institutions have $36.7M invested in HTG Molecular Diagnostics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 16 closing their positions.
1,400% more call options, than puts
Call options by funds: $30K | Put options by funds: $2K
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
4.07% more ownership
Funds ownership: 46.69% → 50.76% (+4.1%)
2% more capital inflows, than outflows
Capital inflows: $11.9M | Capital outflows: $11.6M
13% less funds holding
Funds holding: 54 → 47 (-7)
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
+$7.37M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.68M |
| 3 |
Perkins Capital Management
Wayzata,
Minnesota
|
+$690K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$472K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Private Wealth Partners
Mill Valley,
California
|
-$5.05M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.09M |
| 3 |
Timpani Capital Management
Milwaukee,
Wisconsin
|
-$1.04M |
| 4 |
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.01M |
| 5 |
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$1.01M |
HTGM Hedge Fund Activity: Q4 2018 in Review
47 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics (HTGM) for Q4 2018, worth a combined $36.7M — down 45% from $67M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of HTGM and 9 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 16 added.
The largest buyer was Stonepine Capital Management, adding an estimated $7.37M. The largest seller was Private Wealth Partners, exiting entirely with an estimated $5.05M sold.
- 47 institutional investors held HTG Molecular Diagnostics (HTGM) as of Q4 2018, down from 54 in Q3 2018.
- Funds reported $36.7M of HTG Molecular Diagnostics stock for Q4 2018, down 45% quarter-over-quarter.
- 9 funds opened new HTG Molecular Diagnostics positions in Q4 2018 and 16 closed out, a net change of -7 holders.
- The largest HTG Molecular Diagnostics buyer in Q4 2018 was Stonepine Capital Management, an estimated $7.37M added.
- The largest HTG Molecular Diagnostics seller in Q4 2018 was Private Wealth Partners, an estimated $5.05M sold.
Based on aggregated 13F filings for Q4 2018.